SPDYE22P

Across TCGA pan-cancer cohorts, SPDYE22P RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SPDYE22P’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where SPDYE22P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SPDYE22P is over-expressed in tumor.

BLCA, COAD, and LUSC are the cancer types where SPDYE22P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPDYE22P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.051	.008	5	view →
COAD	Female	II,III,IV	+0.059	.016	4	view →
LUSC	All	All	+0.029	.020	3	view →
STAD	Male	II,III,IV	+0.145	.001	1	view →
LUAD	Male	All	+0.067	.044	1	view →
KIRC	Male	IV	+0.025	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SPDYE22P–BLCA

Open the BLCA breakdown →